Physician profile
Kaitlin Olson
NPI 1477096477
$1,806.16
in general payments reported to CMS, 2019-2025
13 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $82.83 · 2024: $599 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $349.09 | 2024-2025 | Enhertu, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $236.31 | 2024-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $124.98 | 2024 | |
| Genmab U.S., INC. | $124.69 | 2025 | Tivdak |
| Sobi, INC | $124.07 | 2025 | |
| Jazz Pharmaceuticals INC. | $122.54 | 2025 | |
| Agios Pharmaceuticals, INC. | $122.10 | 2025 | Pyrukynd |
| Tersera Therapeutics LLC | $117.16 | 2024 | Zoladex |
| Glaxosmithkline, LLC. | $110.40 | 2025 | |
| Merck Sharp & Dohme LLC | $104.57 | 2025 | Keytruda |
| Syndax Pharmaceuticals, INC. | $99.12 | 2025 | Revuforj |
| Ipsen Biopharmaceuticals, INC | $88.30 | 2025 | Onivyde |
| Novo Nordisk INC | $82.83 | 2023 | Wegovy, Saxenda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.